bioAffinity Technologies, Inc.
Close on Oct 19, 2026
- Market cap
- $18.35M
- P/E (TTM)
- –
- Dividend yield
- –
About bioAffinity Technologies
Services-Commercial Physical & Biological Research, SIC 8731
bioAffinity Technologies, Inc. develops noninvasive diagnostic laboratory tests designed to detect early-stage lung cancer and other diseases of the lung. The company uses flow cytometry combined with automated analysis informed by machine learning. Its primary commercial product, CyPath Lung, analyzes cell populations in sputum, identifying cancer and cancer-related cells to help physicians assess high-risk patients with small pulmonary nodules. Through its subsidiary OncoSelect Therapeutics, the company also conducts research on targeted cancer therapies, including topical treatments for squamous cell skin cancer, while developing companion diagnostics for asthma and chronic obstructive pulmonary disease.
The company delivers its commercial diagnostic testing through its wholly owned subsidiary, Precision Pathology Laboratory Services, an accredited commercial laboratory. Research operations take place at this laboratory and leased space in San Antonio, Texas. bioAffinity Technologies maintains its principal executive offices in San Antonio, Texas.
Summary of the business section of bioAffinity Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- bioAffinity Technologies, Inc.
- Headquarters
- San Antonio, TX
- Address
- 3300 Nacogdoches Road, Suite 216 78217
- Phone
- (210) 698-5334
- Website
- bioaffinitytech.com
- Employees
- 57, Dec 31, 2025
- Industry
- Services-Commercial Physical & Biological Research
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, New York, New York
Stock & identifiers
- Ticker
- BIAF
- Other tickers
- BIAFW
- Exchange
- Nasdaq
- IPO date
- Sep 2, 2022
- Shares outstanding
- 8M, Aug 3, 2026
- Public float
- $22.60M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-15 reverse, Aug 24, 2026; 1-for-30 reverse, Nov 14, 2025; 1-for-30 reverse, Sep 19, 2025
- SEC CIK
- 1712762
- CUSIP
- 09076W117
- ISIN
- US09076W1172
- EIN
- 46-5211056
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven Girgenti | Executive Chairman, Director | 1,089,017 |
| Maria Zannes | President & CEO, Director | 280,359 |
| Xavier Trinidad Reveles | Chief Operating Officer | 41,943 |
| Timothy P. Zannes | Secretary, EVP, Gen. Counsel | 54,765 |
| James Michael Edwards | VP and CFO | 120,128 |
| John J. Oppenheimer | Director | – |
| Roberto Rios | Director | 833 |
Employees
Headcount reported in annual reports
“employ 57 employees at the time of this filing, 21 employed by bioAffinity and 36 employed by PPLS.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 13, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 30, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 7, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 20, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 2, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 2, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |